Clinical Trials Browser

Phase 2 × Lymphoma, Extranodal NK-T-Cell × avelumab × Clear all

NCT03439501 2021-09-24

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell